Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity
Lipids · 2023-05 · 58 (3) · 107-115
DOI: 10.1002/lipd.12367 ↗At a glance
Journal article in Lipids, published online on 2023-02-27. Written by Kelli A Lytle and 4 co-authors. Institution: Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Obesity, Morbid, Insulin Resistance. Cited 7 times so far (Crossref); 36 references. Funded by: NCRR NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (original language)
We investigated the relationships between ceramide species concentrations in liver, plasma and very low‐density lipoproteins (VLDL) particles of humans with obesity as well as the relationships between hepatic fat content and hepatic ceramide concentrations and proportional distribution. Twenty‐five obese (body mass index >35 kg/m 2 ) adults participated in this study. Plasma, VLDL and hepatocellular ceramide concentrations were measured by liquid chromatography/tandem mass spectrometry. The proportionate distribution of measured ceramide species differed between liver, whole plasma and the VLDL fraction. We found significant, positive correlations between the proportion of C14:0, C18:0, C20:0 and C24:1 ceramide in the liver and whole plasma ( γ = 0.491, p = 0.013; γ = 0.573, p = 0.003; γ = 0.479, p = 0.015; γ = 0.716, p = 0.00006; respectively). In contrast, only the proportional contribution of C24:1 ceramide correlated positively between VLDL and liver ( γ = 0.425, p = 0.013). The percent hepatic fat correlated positively with the proportion of C18:1, C18:0 and C20:0 hepatic ceramides ( γ = 0.415, p = 0.039; γ = 0.426, p = 0.034; γ = 0.612, p = 0.001; respectively), but not with total hepatic ceramide concentration. The proportions of whole plasma ceramide subspecies, especially C14:0, C18:0, C20:0 and C24:1chain length, are reflective of those of hepatic ceramide subspecies in obese humans; these appear to be markers of hepatic ceramide species composition.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Chonnam National University Medical School, Gwangju, Republic of Korea.
- Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Bendigo Health, Bendigo, Victoria, Australia.
ORCID profiles: Michael D Jensen
Funding
- NCRR NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Institutes of Health
- American Diabetes Association
Cite
APA
Lytle, K. A., Chung, J. O., Bush, N. C., Triay, J. M., & Jensen, M. D. (2023). Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity. Lipids, 58(3), 107-115. https://doi.org/10.1002/lipd.12367
Vancouver
Lytle KA, Chung JO, Bush NC, Triay JM, Jensen MD. Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity. Lipids. 2023;58(3):107-115. doi:10.1002/lipd.12367
BibTeX
@article{Lytle2023,
author = {Lytle, Kelli A and Chung, Jin Ook and Bush, Nikki C and Triay, Jessica M and Jensen, Michael D},
title = {Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity},
journal = {Lipids},
year = {2023},
volume = {58},
number = {3},
pages = {107--115},
doi = {10.1002/lipd.12367}
}
EUVIMED